(Press-News.org) Antidepressants are the most widely used treatment for people with moderate to severe depression. However, up to two thirds of people with depression don't respond fully to this type of treatment. New findings, published in The Lancet, have shown cognitive behavioural therapy (CBT)*, provided in addition to usual care, can reduce symptoms of depression and help improve patients' quality of life.
This is the first large-scale trial to test the effectiveness of CBT — a type of talking psychotherapy — given in addition to usual care that includes antidepressants. The National Institute for Health Research Health Technology Assessment (NIHR HTA) Programme-funded CoBalT study aimed to determine the best 'next step' treatment for people whose depression had not responded to medication alone.
The CoBaIT team, comprising researchers from the Universities of Bristol, Exeter and Glasgow, recruited 469 patients aged 18- to 75-years with treatment-resistant depression for the randomised controlled trial. Patients were split into two groups: 235 patients continued with their usual care from the GP, which included continuing on antidepressant medication, and 234 patients were treated with CBT in addition to usual care from their GP. Researchers followed-up 422 patients (90 per cent) at six months and 396 (84 per cent) at 12 months to compare their progress.
At six months, 46 per cent of those who received CBT in addition to usual care had improved, reporting at least a 50 per cent reduction in symptoms of depression, compared to 22 per cent of those who continued with usual care alone. This beneficial effect was maintained over 12 months.
The findings demonstrate that CBT provided in addition to usual care including antidepressant medication is an effective treatment that reduces depressive symptoms, and improves the quality of life in patients whose depression has not responded to the most common first-line treatment for depression in primary care.
Dr Nicola Wiles, the study's lead author and a Senior Lecturer in the University of Bristol's School of Social and Community Medicine, said: "Antidepressants are often the first-line treatment for depression — a major public health problem with the World Health Organisation estimating that over 300 million people are affected globally. However, in many countries, access to psychological treatments such as CBT is limited to people who can afford to pay, or those with health insurance. These findings emphasise the importance of increasing the availability of psychological therapy. While there have been initiatives to increase access to such treatments in both the UK and Australia, worldwide initiatives are rare, and even in the UK many people who have not responded to antidepressants do not get psychological treatment. Our study suggests that by investing in psychological services it is possible to reduce the significant burden to patients and healthcare systems that is associated with non-response to antidepressant medication.
"Furthermore, it is important to acknowledge that while we found CBT was an effective treatment for this patient group, not everyone who received CBT improved. It is therefore essential that we invest in further research in this area to investigate alternative treatment options, both pharmacological and non-pharmacological, for the significant number of patients whose depression does not get better following treatment with antidepressants."
Willem Kuyken, Professor of Clinical Psychology at the University of Exeter, added: "This trial provides further evidence that psychological treatments like cognitive therapy can provide substantive and lasting help to people who suffer depression. The Mood Disorders Centre, one of the participating sites, aims to make evidence-based psychological approaches as accessible as possible to people suffering depression. This trial demonstrates that people with complex and longstanding needs who have not responded to antidepressants can derive substantive and lasting benefit from CBT delivered by well trained therapists. Showing that 40 per cent of people who had been in cognitive therapy were largely free of symptoms at 12 months is really important because it bodes well for their longer-term recovery."
John Campbell, Professor of General Practice at the University of Exeter Medical School, commented: "Depression is a very common illness, encountered frequently by GPs and their patients. While drug treatments can be very effective, not all patients will respond well to treatment. For some patients, the experience of depression can be particularly difficult. We were delighted that so many patients, GPs, and practices helped us with this research. The results we present today show that for some patients, the addition of a 'talking therapy' such as CBT can be very effective in treating the depression and helping resolve disabling symptoms. GPs and their patients can take real encouragement from these findings which provide real support for the use of CBT in patients where other treatments may have failed."
Chris Williams, Professor of Psychosocial Psychiatry at the University of Glasgow, added: "This research is also of great importance because it used a CBT intervention alongside treatment with antidepressants. It confirms how these approaches — the psychological and physical — treatments can complement each other. It was also encouraging because we found the approach worked to good effect across a wide range of people of different ages and living in a variety of settings."
Emer O'Neill, Chief Executive of Depression Alliance, the leading UK charity for people affected by depression, added: "Over the last few years there has been a significant improvement in lifting the stigma associated with depression, and the services available to help treat it.
"However, this marks just the beginning as for years our members have been asking for access to a wide range of peer-support services. We are delighted to see this research as it now provides the evidence that a range of treatments such as cognitive behavioural therapy and medication is vital to continuing this success."
### END
Cognitive behavioral therapy can reduce depression in those haven't responded to antidepressants
2012-12-07
ELSE PRESS RELEASES FROM THIS DATE:
New antidepressant acts very rapidly and is long lasting
2012-12-07
A first-of-its-kind antidepressant drug discovered by a Northwestern University professor and now tested on adults who have failed other antidepressant therapies has been shown to alleviate symptoms within hours, have good safety and produce positive effects that last for about seven days from a single dose.
The novel therapeutic targets brain receptors responsible for learning and memory -- a very different approach from existing antidepressants. The new drug and others like it also could be helpful in treating other neurological conditions, including schizophrenia, ...
Ethiopians and Tibetans thrive in thin air using similar physiology, but different genes
2012-12-07
Durham, NC — Scientists say they have pinpointed genetic changes that allow some Ethiopians to live and work more than a mile and a half above sea level without getting altitude sickness. The specific genes differ from those reported previously for high-altitude Tibetans, even though both groups cope with low-oxygen in similar physiological ways, the researchers report.
If confirmed, the results may help scientists understand why some people are more vulnerable to low blood oxygen levels caused by factors other than altitude — such as asthma, sleep apnea, heart problems ...
The world's big trees are dying
2012-12-07
The largest living organisms on the planet, the big, old trees that harbour and sustain countless birds and other wildlife, are dying.
A report by three of the world's leading ecologists in today's issue of the journal Science warns of an alarming increase in deathrates among trees 100-300 years old in many of the world's forests, woodlands, savannahs, farming areas and even in cities.
"It's a worldwide problem and appears to be happening in most types of forest," says lead author Professor David Lindenmayer of the ARC Centre of Excellence for Environmental Decisions ...
The skills that make us a good partner make us a good parent
2012-12-07
December 7, 2012 - Being a good partner may make you a better parent, according to a new study. The same set of skills that we tap to be caring toward our partners is what we use to nurture our children, researchers found.
The study sought to examine how caregiving plays out in families – "how one relationship affects another relationship," says Abigail Millings of the University of Bristol, lead author of the work published online this week in Personality and Social Psychology Bulletin. "We wanted to see how romantic relationships between parents might be associated ...
Obesity and overeating during menopause together promote breast tumor growth and progression
2012-12-07
PHILADELPHIA — Obese women might be able to eliminate their increased risk for postmenopausal breast cancer by taking measures during perimenopause to prevent weight gain and to therapeutically control the metabolic effects of their obesity, according to the results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.
"Obese postmenopausal women have increased risk for breast cancer and poorer clinical outcomes compared with postmenopausal women who are lean," said Paul S. MacLean, Ph.D., associate professor of ...
Existing drugs may help more breast cancer patients
2012-12-07
More patients can benefit from highly effective breast cancer drugs that are already available, according to DNA sequencing studies by researchers at Washington University School of Medicine in St. Louis and other institutions.
The investigators found that some women with the HER2 negative subtype may benefit from anti-HER2 drugs even though standard tests don't indicate they are candidates for the drugs.
"These patients are going to be missed by our routine testing for HER2 positive breast cancer," says Ron Bose, MD, PhD, assistant professor of medicine. "Currently ...
Protein tied to cancer-drug resistance in mice
2012-12-07
SAN ANTONIO, TX (December 7, 2012)—Blocking a specific protein renders tumors more vulnerable to treatment in mice, suggesting new therapies could eventually achieve the same in humans, according to new research from Fox Chase Cancer Center to be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium on Friday, December 7, 2012.
"Hopefully, with further testing, this research could one day result in a new therapy that blocks the effect of this protein and, in turn, boosts the effects of cancer drugs," says study author Elizabeth Hopper-Borge, PhD, Assistant ...
Study compares standard against newer treatment in women whose breast cancer has spread
2012-12-07
(Lebanon, NH, 12/7/12) — Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival. This study was presented today by Peter A. Kaufman, M.D., during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.
"We didn't show a statistically significant superiority of eribulin over capecitabine, which was our goal," said Peter A. Kaufman, ...
The effect of treating institution on outcomes in head and neck cancer
2012-12-07
Alexandria, VA — Patients with head and neck cancer receiving radiation treatment at an academic center have a higher survival rate than those receiving treatment at a community center, according to a study in the December 2012 issue of Otolaryngology–Head and Neck Surgery.
"Despite similar rates of treatment completion and rate of treatment breaks between groups, patients treated in academic centers had more advanced cancer but better survival," the authors state in their conclusion.
The study evaluated differences in patient characteristics, treatment, and cancer ...
Point of light
2012-12-07
PASADENA, Calif.—As technology advances, it tends to shrink. From cell phones to laptops—powered by increasingly faster and tinier processors—everything is getting thinner and sleeker. And now light beams are getting smaller, too.
Engineers at the California Institute of Technology (Caltech) have created a device that can focus light into a point just a few nanometers (billionths of a meter) across—an achievement they say may lead to next-generation applications in computing, communications, and imaging.
Because light can carry greater amounts of data more efficiently ...